Latigo reports Q3 2026 results, names new CEO, adds opioid arm to Phase 3 trial
Latigo said its Phase 3 bunionectomy and safety trials of onzotrigine remain on track for 2027 topline data as Todd Smith succeeds Nima Farzan as CEO.
SEC filing (2)
Latest
6 stories
Thursday, November 5
Tuesday, November 3
Pfizer raises 2026 guidance after Q3, reports pipeline progress and new CFO
Pfizer lifted full-year revenue and EPS guidance on third-quarter results and detailed regulatory approvals for Talzenna, Tukysa and a positive Elrexfio Phase 3 readout.
SEC filing (9)
IDEAYA completes darovasertib NDA, halts Phase 3 OptimUM-010 for enrollment issues
The company reported third-quarter 2026 results alongside an FDA submission, a trial closure expected to save up to $125 million, and $1.15 billion in cash.
SEC filing (14)
Monday, November 2
Emergent BioSolutions cuts 2026 revenue and EBITDA guidance as Q3 sales fall 52%
The company also disclosed a CFO transition, a debt repurchase, and a $24 million CYFENDUS contract modification as it narrows its full-year outlook.
SEC filing (23)
Thursday, October 29
Merck posts Q3 2026 results with oncology approvals and new sac-TMT regulatory filing
Merck reported $18.1 billion in third-quarter sales and detailed FDA approvals, a priority BLA filing for sac-TMT, and new guidance including one-time charges tied to the Cidara and Terns deals.
SEC filing (2)
Tuesday, October 27
Artiva Biotherapeutics halts AlloNK development, cuts staff by 94%
The company stopped work on its lead NK cell therapy after two patient deaths and weak durability data, and is now reviewing strategic options including a possible sale or dissolution.
SEC filing (4)